LOS ANGELES--(BUSINESS WIRE)--DRX, a leading provider of healthcare comparison tools, technology and data, today announced the addition of pancreatic enzyme products as the 100th therapeutic class covered by DRX’s prescription drug comparison database, DrugCompare. With this latest addition, the DrugCompare database now covers nearly 85% of the top 200 pharmaceutical drugs sold in the United States.i A DRX analysis shows that switching drugs within the pancreatic enzyme product class can result in significant cost savings for many patients through reductions in direct drug costs or copays.
